文献速递细菌感染、耐药与抗菌药物医院感染防控新发突发、热带与寄生虫病

儿童金黄色葡萄球菌菌血症:临床谱与不良结局预测因素

Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome.
PubMed 文献 · Clin Infect Dis · 2022-01-01

ISAIAH 是一项在澳大利亚和新西兰开展的前瞻性横断面研究,纳入 2017–2018 年 24 个月内住院的儿童金黄色葡萄球菌菌血症(SAB)病例共 552 例(发病率 4.4/10 万/年)。研究显示 90 天死亡率虽低,但约三分之一患儿出现住院超过 30 天、入住 ICU、复发或死亡的复合不良结局;坏死性肺炎和多灶性感染为死亡预测因素,感染科会诊具保护作用,经验性万古霉素与肾毒性相关。

要点

  • 儿童 SAB 发病率 4.4/10 万/年,原住民、低社会经济地区及新生儿占比过高。
  • 坏死性肺炎、多灶性感染、多器官功能障碍、早产及经验性万古霉素为死亡预测因素。
  • 感染科会诊与更低死亡率相关,经验性万古霉素与肾毒性相关。

核心结论

  • 儿童 SAB 发病率较高,坏死性肺炎和多灶性感染首次在儿科被确定为死亡预测因素,感染科会诊具保护作用。

研究设计与样本

  • ISAIAH 为前瞻性横断面研究,纳入澳大利亚和新西兰 24 个月(2017–2018)住院的儿童 SAB 病例共 552 例。

主要发现

  • 552 例 SAB 发病率 4.4/10 万/年,原住民、低社会经济地区及新生儿占比过高。
  • 90 天死亡率低,但三分之一患儿出现住院超过 30 天(26%)、入住 ICU(20%)、复发(4%)或死亡(3%)的复合结局。
  • 死亡预测因素包括早产(aOR 16.8,95%CI 1.6–296.9)、多灶性感染(aOR 22.6,95%CI 1.4–498.5)、坏死性肺炎(aOR 38.9,95%CI 1.7–1754.6)、多器官功能障碍(aOR 26.5,95%CI 4.1–268.8)及经验性万古霉素(aOR 15.7,95%CI 1.6–434.4)。
  • MRSA 及万古霉素谷浓度目标未影响生存,但经验性万古霉素与肾毒性相关(OR 3.1,95%CI 1.3–8.1)。

关键数值与推荐

  • 死亡预测因素 aOR 值:早产 16.8(95%CI 1.6–296.9)、多灶性感染 22.6(95%CI 1.4–498.5)、坏死性肺炎 38.9(95%CI 1.7–1754.6)、多器官功能障碍 26.5(95%CI 4.1–268.8)、经验性万古霉素 15.7(95%CI 1.6–434.4)。
  • 经验性万古霉素与肾毒性 OR 3.1(95%CI 1.3–8.1)。

临床怎么用

  • 对儿童 SAB 应早期识别坏死性肺炎、多灶性感染等高危因素并积极干预。
  • 建议感染科参与儿童 SAB 管理以改善结局。
  • 需重新评估儿童万古霉素谷浓度目标并限制不必要的经验性万古霉素暴露以减少肾毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Staphylococcus aureus is a common cause of bacteremia, yet the epidemiology and predictors of poor outcome remain inadequately defined in childhood. METHODS: ISAIAH (Invasive Staphylococcus aureus Infections and Hospitalizations in children) is a prospective, cross-sectional study of S. aureus bacteremia (SAB) in children hospitalized in Australia and New Zealand over 24 months (2017-2018). RESULTS: Overall, 552 SABs were identified (incidence 4.4/100 000/year). Indigenous children, those from lower socioeconomic areas and neonates were overrepresented. Although 90-day mortality was infrequent, one-third experienced the composite of: length of stay >30 days (26%), intensive care unit admission (20%), relapse (4%), or death (3%). Predictors of mortality included prematurity (adjusted odds ratio [aOR],16.8; 95% confidence interval [CI], 1.6-296.9), multifocal infection (aOR, 22.6; CI, 1.4-498.5), necrotizing pneumonia (aOR, 38.9; CI, 1.7-1754.6), multiorgan dysfunction (aOR, 26.5; CI, 4.1-268.8), and empiric vancomycin (aOR, 15.7; CI, 1.6-434.4); while infectious diseases (ID) consultation (aOR, 0.07; CI .004-.9) was protective. Neither MRSA nor vancomycin trough targets impacted survival; however, empiric vancomycin was associated with nephrotoxicity (OR, 3.1; 95% CI 1.3-8.1). CONCLUSIONS: High SAB incidence was demonstrated and for the first time in a pediatric setting, necrotizing pneumonia and multifocal infection were predictors of mortality, while ID consultation was protective. The need to reevaluate pediatric vancomycin trough targets and limit unnecessary empiric vancomycin exposure to reduce poor outcomes and nephrotoxicity is highlighted. One in 3 children experienced considerable SAB morbidity; therefore, pediatric inclusion in future SAB comparator trials is paramount to improve outcomes.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Campbell AJ, Al Yazidi LS, Phuong LK, et al. Pediatric Staphylococcus aureus Bacteremia: Clinical Spectrum and Predictors of Poor Outcome. Clin Infect Dis. 2022. PMID: 34089594. doi:10.1093/cid/ciab510

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。